Company insider dossier

INmune Bio Inc insider intelligence

INMB filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.

Terminal chart Weekly report Factor intelligence Healthcare Biotechnology Data API
78/100

Conviction accumulation

44/100 confidence
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
Latest evidence
2 Jul 2026

Investment committee read

Conviction accumulation

Priced common-share acquisitions carry more weighted evidence than disposals after freshness, role, size, and duplicate controls.

Research constructive setups

Evidence in favour

  • 3 distinct acquisition events survive duplicate and security-type controls.
  • Participation spans 3 named insiders rather than one filing source.

Decision risks

  • The latest qualifying filing is more than 30 days old.
Conviction78Conviction accumulation
Confidence44Thin evidence
Named insiders3participating in the tape
Controlled events3directional common-share events
Acquisition value$43.4Knormalized amount
Disposal value$3.9Knormalized amount

Price confirmation map

Weekly price with common-share events

Acquisitions and disposals are aligned to the nearest completed weekly bar.

7.866.184.492.811.12 Acquisition · 2 Jul 2026 · $20.7KAcquisition · 2 Jul 2026 · $12.6KAcquisition · 2 Jul 2026 · $10.1K
Mar 2025Sep 2026
Weekly closeCommon-share acquisitionCommon-share disposal

Market confirmation

Price and trend context

Latest close
2.33 USD
One-week move
+5.0%
Four-week move
+0.4%
Fair-value gap
-58.4%
Trend signal
Active
Relative strength
26.2

Directional balance

Controlled event mix

100.0%acquisition
Acquisition events
3
Disposal events
0
Net value
$39.6K

Cadence

Twelve-week filing pressure

Volume shows attention. Controlled events determine direction.

629 Jun
006 Jul
013 Jul
020 Jul
027 Jul
003 Aug
010 Aug
017 Aug
024 Aug
031 Aug
007 Sep
014 Sep

Named participants

Insider conviction by person

JUDA, SCOTTDirector721 events
LOWDELL, MARK WILLIAMChief Scientific Officer721 events
MOSS, DAVID JDirector, Chief Executive Officer721 events

Evidence quality

Security and transaction context

Common equity3
Equity compensation0
Options and derivatives3
Other securities0

Role architecture

Who is participating

CEO and chair2
Director2
Other executive2

Transaction evidence

Auditable INMB filing ledger

Showing 1 to 6 of 6.

JUDA, SCOTTDirector
AcquisitionCommon equity
14801 sharesCommon Stock
$20.7KDirectional evidence
MOSS, DAVID JDirector, Chief Executive Officer
AcquisitionCommon equity
9014 sharesCommon Stock
$12.6KDirectional evidence
LOWDELL, MARK WILLIAMChief Scientific Officer
AcquisitionCommon equity
7211 sharesCommon Stock
$10.1KDirectional evidence
JUDA, SCOTTDirector
DisposalOptions and derivatives
14801 sharesCommon Stock Purchase Warrant
$1.9KContext evidence
MOSS, DAVID JDirector, Chief Executive Officer
DisposalOptions and derivatives
9014 sharesCommon Stock Purchase Warrant
$1.1KContext evidence
LOWDELL, MARK WILLIAMChief Scientific Officer
DisposalOptions and derivatives
7211 sharesCommon Stock Purchase Warrant
$901Context evidence

Reading the dossier

Direction and confidence are separate

Conviction

The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.

Confidence

Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.

Disposals

Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.

Price confirmation

The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.

Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.

Evidence context